Mycophenolate: Boxed-Warning Pregnancy Prevention Requirements for Transplant and Autoimmune Use, Bulk Export Supply from India
Mycophenolate carries an FDA boxed warning for embryo-fetal toxicity, and the regulatory response differs by market: the US FDA REMS program for mycophenolate has been eliminated as of 2026 (the current FDA-approved label no longer contains a REMS requirement), while the EU Pregnancy Prevention Programme remains a separate, mandatory requirement under EMA-approved labelling. For a transplant or autoimmune-disease pharmacy, that governs what has to arrive with the shipment, not just what treats the patient. M Care supplies mycophenolate across 27 catalogue lines, both mofetil and the enteric-coated sodium salt, sourced from WHO-GMP certified Indian manufacturers, with documentation built around the pregnancy-prevention requirement that actually applies in your market.
Mycophenolate mofetil exporter and bulk supplier from India.
M Care exports mycophenolate under standard pharmaceutical incoterms with cold-chain-independent packing, since the molecule is stable at controlled room temperature and does not require refrigerated freight. Export documentation for each shipment includes a certificate of analysis matched to the batch, a certificate of pharmaceutical product or free sale certificate from the country of manufacture, and packing lists structured for customs clearance in the destination market. Because mycophenolate (both mofetil and the enteric-coated sodium salt) is a boxed-warning teratogen, we include the manufacturer's current package insert and pregnancy-prevention labelling with every consignment so the importing pharmacy has that language in hand at the point of receipt, not sourced separately after customs release.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Immunosuppressant, inosine monophosphate dehydrogenase (IMPDH) inhibitor, sourced and documented for export.
Mycophenolate carries an FDA boxed warning and an EU Pregnancy Prevention Programme for embryo-fetal toxicity, a fact that governs how a receiving pharmacy must handle it before the mechanism of action does. Mycophenolate mofetil is a prodrug of mycophenolic acid, an inosine monophosphate dehydrogenase (IMPDH) inhibitor used as maintenance immunosuppression to prevent rejection after kidney, heart and liver transplantation, usually alongside a calcineurin inhibitor and a corticosteroid, and increasingly in autoimmune indications such as lupus nephritis. Mycophenolate sodium, an enteric-coated formulation, is used in the same indications and is not interchangeable with mofetil on a milligram basis. The receiving pharmacy therefore needs to verify current requirements and have its own counselling, contraception verification and record-keeping protocol in place before the product reaches the shelf, not assembled after the shipment has already cleared customs.
Active ingredient
Mycophenolate mofetil. Immunosuppressant, inosine monophosphate dehydrogenase (IMPDH) inhibitor.
Forms and strengths
250 mg (mofetil); 500 mg (mofetil); 1 g (mofetil); 180 mg (sodium, enteric-coated); 360 mg (sodium, enteric-coated).
Indications
Mycophenolate mofetil is a prodrug of mycophenolic acid, an IMPDH inhibitor used as maintenance immunosuppressive therapy to prevent organ rejection in kidney, heart and liver transplant recipients, typically combined with a calcineurin inhibitor and a corticosteroid, and in autoimmune indications such as lupus nephritis. Mycophenolate sodium is an enteric-coated formulation used in the same indications and is not interchangeable with mofetil on a milligram basis. The molecule carries an FDA boxed warning for embryo-fetal toxicity. As of 2026, the US FDA REMS program for mycophenolate has been eliminated per the current FDA-approved label, while mycophenolate remains subject to a mandatory Pregnancy Prevention Programme under EMA-approved product information in the EU. Regulatory status differs by market and can change, so current requirements should be confirmed against the relevant national regulator or manufacturer label.
Administration
Oral. Tablets (including enteric-coated), capsules and oral suspension.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Demand comes from transplant centre pharmacies, hospital procurement departments and licensed pharmaceutical importers in the UK and EU, the Gulf and wider GCC, Sub-Saharan and North Africa, Latin America, Southeast Asia and the CIS, where kidney and liver transplant programmes rely on generic mycophenolate to keep maintenance immunosuppression affordable. Tender desks sourcing for public hospital formularies and distributors supplying private transplant units are the two recurring buyer profiles. Because the molecule sits under pregnancy-prevention regulatory controls in most destination markets (a mandatory EU Pregnancy Prevention Programme, and market-specific requirements elsewhere), buyers are almost always regulatory affairs or clinical pharmacy staff who already handle restricted immunosuppressants, not general wholesale accounts.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on mycophenolate mofetil.
A receiving pharmacist should verify the batch against the manufacturer's certificate of analysis for assay, dissolution and related-substance limits before release, and confirm the pack carries the current boxed warning and pregnancy-prevention labelling language, since mycophenolate labelling has changed more than once as US REMS and EU Pregnancy Prevention Programme requirements were updated (the US REMS program has been eliminated as of 2026; the EU programme remains mandatory and unchanged). Formulation matters clinically: mycophenolate mofetil and mycophenolate sodium are not interchangeable on a milligram-for-milligram basis, and a switch between them, or between an innovator and a generic line, should be flagged for prescriber review rather than substituted automatically. Antacids and cholestyramine are labelled to reduce mycophenolic acid absorption; any resulting dose adjustment is a prescriber decision and should already sit in the receiving centre's own protocol rather than being inferred from the pack insert alone. Indian brand naming makes the salt distinction more hazardous, not less: catalogue lines are routinely listed as mycophenolate mofetil at 180mg or 360mg when those strengths are the sodium salt, usually flagged only by an S suffix in the brand name. Order against the salt and the strength together. We confirm the salt on the proforma before dispatch rather than after.
The documentation pack a regulator actually asks for.
Each mycophenolate line supplied by M Care, both mofetil and the enteric-coated sodium salt, is sourced from an Indian manufacturer holding WHO-GMP certification for the relevant dosage form; M Care itself does not hold WHO-GMP or WHO-PQ status, as a merchant-exporter rather than a manufacturer. The documentation pack assembled per shipment covers the manufacturer's GMP certificate, a certificate of analysis specific to the batch, stability data supporting the labelled shelf life, and a certificate of pharmaceutical product or free sale certificate for import registration. Buyers preparing an eCTD or CTD submission receive Module 3 quality data from the manufacturer on request, structured for the destination regulator. Because pregnancy-prevention labelling obligations for mycophenolate differ by market (the US FDA REMS program has been eliminated as of 2026, while the EU Pregnancy Prevention Programme remains mandatory), we forward the manufacturer's current package insert and any applicable medication guide so the importer's own regulatory file stays aligned with the version actually shipped, not an older label on record.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
What a buyer should know before this line enters a formulary.
We publish the awkward facts alongside the useful ones. A supplier who omits them is not saving you work, only deferring it.
FDA boxed warning: embryo-fetal toxicity (mycophenolate mofetil and mycophenolate sodium are both confirmed human teratogens)
As of August 2026, the FDA-mandated Mycophenolate REMS program has been eliminated in the United States: the current FDA-approved label (revised July 2026) no longer contains a REMS requirement. Confirm current status at mycophenolaterems.com or the manufacturer's current label before purchase, since regulatory status can change
Mycophenolate-containing medicines remain subject to a separate, mandatory EU Pregnancy Prevention Programme under EMA-approved product information: two negative pregnancy tests before starting treatment, contraception for women of childbearing potential before, during and for six weeks after stopping treatment, and contraception for men or their partners during treatment and for 90 days after. This EU requirement is unchanged by the US REMS elimination
Increased risk of first-trimester pregnancy loss and congenital malformations (including external ear, facial, limb, cardiac, esophageal, renal and nervous-system anomalies) with in-utero exposure, per FDA and EMA labelling
Contraindicated in pregnancy unless no suitable alternative exists to prevent transplant rejection
M Care Exports is a merchant-exporter, not a manufacturer, and does not hold WHO-GMP or WHO-PQ certification directly; product is sourced from WHO-GMP certified Indian manufacturers
Adjacent lines procurement desks order alongside mycophenolate mofetil.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for mycophenolate mofetil.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Mycophenolate mofetil supply, the specific questions.
Why does mycophenolate carry a boxed warning, and what does that mean for our pharmacy?
Mycophenolate, both the mofetil and sodium salts, is a confirmed human teratogen: FDA and EMA labelling describe an increased risk of first-trimester pregnancy loss and congenital malformations, including ear, facial, limb, cardiac and renal anomalies, with in-utero exposure. For a receiving pharmacy this means patient counselling and contraception verification need to be part of the dispensing workflow, not an afterthought.
Does M Care hold WHO-GMP or WHO-PQ certification directly?
No. M Care is a merchant-exporter, not a manufacturer, and does not hold WHO-GMP or WHO-PQ status itself. Every mycophenolate line we supply is sourced from Indian manufacturers that hold WHO-GMP certification for the relevant dosage form, and their GMP certificates are included in the documentation pack for each shipment.
What contraception and pregnancy prevention requirements apply in our market?
In the EU, EMA-approved product information requires a mandatory Pregnancy Prevention Programme: two negative pregnancy tests before starting treatment, contraception for women of childbearing potential before, during and for six weeks after stopping mycophenolate, and contraception for men or their partners during treatment and for 90 days after. In the United States, the FDA-mandated Mycophenolate REMS program has been eliminated as of 2026: the current FDA-approved label no longer contains a REMS requirement. Regulatory status differs by market and can change, so confirm current requirements with the relevant national regulator or the manufacturer's current label before purchase.
Is M Care ISO certified and CDSCO licensed?
Yes. M Care Exports holds ISO 9001:2015 certification for its quality management system and is CDSCO licensed as a merchant-exporter in India. These are M Care's own credentials as an exporter; manufacturing-level certifications such as WHO-GMP sit with the sourcing manufacturers, not with M Care.
Can mycophenolate mofetil and mycophenolate sodium be substituted for each other?
No, not on a simple milligram basis. The two salts have different bioavailability profiles and are not automatically interchangeable; a change in formulation or brand should be reviewed by the prescriber rather than made at the dispensing or procurement level.
What documentation is included with a mycophenolate shipment?
Each consignment ships with a certificate of analysis matched to the batch, the manufacturer's GMP certificate, a certificate of pharmaceutical product or free sale certificate, stability data supporting shelf life, and the manufacturer's current package insert with pregnancy prevention labelling. CTD Module 3 quality data is available from the manufacturer on request for import registration.
Which strengths and formulations does M Care's catalogue cover?
The catalogue spans 27 mycophenolate product lines: mycophenolate mofetil in 250mg, 500mg and 1g tablet and capsule strengths, and mycophenolate sodium in 180mg and 360mg enteric-coated tablets, plus oral suspension presentations. Specific line availability by strength and form is confirmed at enquiry stage rather than published as a fixed price list.
Your catalogue lists 180mg and 360mg lines as mycophenolate mofetil. Are they?
Those strengths are mycophenolate sodium, the enteric-coated salt, even where a brand name or listing calls them mofetil. The 180mg and 360mg sodium strengths correspond roughly to 250mg and 500mg of mofetil, and the two are not interchangeable milligram for milligram. Specify the salt and the strength together on the enquiry and we will confirm both on the proforma before dispatch.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-22.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.